A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
Phase of Trial: Phase II
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2018 Planned End Date changed from 31 Jul 2024 to 30 Sep 2024.
- 28 Sep 2018 Planned primary completion date changed from 31 Jul 2021 to 30 Sep 2021.
- 28 Sep 2018 Status changed from not yet recruiting to recruiting.